scholarly journals Treatment of selective antibody deficiency with IVIG resulting in decreased frequency of streptococcal infection and improvement of guttate psoriasis

2017 ◽  
Vol 23 (8) ◽  
Author(s):  
Maulik M Dhandha ◽  
Elaine C Siegfried ◽  
Alan P Knutsen
Keyword(s):  
Streptococcal Infection ◽  
Antibody Deficiency ◽  
Guttate Psoriasis

Guttate psoriasis triggered by perianal streptococcal infection

2017 ◽  
Vol 42 (5) ◽  
pp. 536-538 ◽  
Author(s):  
F. M. Garritsen ◽  
D. E. Kraag ◽  
M. de Graaf
Keyword(s):  
Streptococcal Infection ◽  
Guttate Psoriasis

scholarly journals Psoriasis Gutata - Laporan Kasus

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Julieta D. P. Dotulong ◽  
Charly M. M. Korompis ◽  
Herry E. J. Pandaleke
Keyword(s):  
Streptococcal Infection ◽  
Topical Steroid ◽  
The Body ◽  
Trigger Factor ◽  
First Line ◽  
First Line Therapy ◽  
History Of ◽  
Erythematous Plaques ◽  
Guttate Psoriasis ◽  
Case Diagnosis

Abstract: Guttate psoriasis (GP) is a variant of psoriasis with typical drop-shaped lesions sized 0.5-1 cm in diameter, localized especially in the upper part of the body and proximal extremities. It usually occurs in young adult. We reported a female,11 years old, with red, itchy, and scaly patches distributed nearly all over the body. There was a history of sore throat. Dermatologic status showed multiple erythematous plaques which were miliar to numular, discrete, and were covered with layered silvery white scales. The Auspitz sign, wax spot phenomenon, and ASTO were positive. The histopathologic examination showed para-keratosis and Munro microabcesses. The patient treated with topical steroid for 4 weeks made improvement. Conclusion: In this case, diagnosis of guttate psoriasis was based on anamnesis, examination, and supporting examinations. Streptococcal infection was suspected as the trigger factor due to the positive ASTO examination. Topical steroid as the first line therapy for mild to moderate psoriasis made great improvement.Keywords: guttate psoriasis, streptococcal infectionAbstrak: Psoriasis gutata (PG) merupakan varian dari psoriasis. Gambaran khasnya seperti tetesan air dengan diameter 0,5-1 cm, di badan bagian atas dan ekstremitas proksimal. Sering terjadi pada dewasa muda. Kami melaporkan kasus seorang perempuan berusia 11 tahun dengan bercak merah meninggi, bersisik, disertai gatal pada hampir seluruh tubuh. Riwayat nyeri menelan positif. Riwayat pengobatan sebelumnya disangkal. Status dermatologis ditemukan plak eritem, multipel, miliar-numular, diskret, ditutupi skuama berlapis warna putih keperakan. Pemeriksaan tanda Auspitz, fenomena bercak lilin, dan ASTO positif. Pada pemeriksaan histopatologik didapatkan adanya parakeratosis dan mikroabses Munro. Terapi steroid topikal potensi tinggi selama 4 minggu menunjukkan perbaikan. Simpulan: Pada kasus ini diagnosis psoriasis gutata ditegakkan berdasarkan anamnesis, pemeriksaan fisik, dan pemeriksaan penunjang yang khas. Infeksi streptokokus diduga sebagai faktor pencetus berdasarkan hasil pemeriksaan ASTO. Terapi steroid topikal merupakan lini pertama untuk psoriasis ringan sampai sedang memperlihatkan perbaikan yang nyata.Kata kunci: psoriasis gutata, infeksi streptokokus

Ustekinumab in the Treatment of Guttate Psoriasis and Crohn's Disease: A Case Report

2017 ◽  
Vol 2 (2) ◽  
pp. 54-58
Author(s):  
Jonas A. Adalsteinsson ◽  
Yasmin Amir
Keyword(s):  
Crohn’S Disease ◽  
Case Report ◽  
Crohn's Disease ◽  
Streptococcal Infection ◽  
Therapeutic Option ◽  
Phase Iii ◽  
Complete Regression ◽  
Tnf Inhibitor ◽  
Phase Iii Trials ◽  
Guttate Psoriasis

Psoriasis and Crohn's disease are autoimmune diseases believed to share a similar pathogenesis. Ustekinumab is FDA-approved for treatment of psoriasis in 45 mg and 90 mg dosages and is undergoing phase III trials for Crohn's disease in higher dosages. Data on ustekinumab in guttate psoriasis (GP) are limited. We report the case of a 21-year-old female with Crohn's disease on adalimumab who developed severe, generalized GP 2 months after a streptococcal infection. Her GP did not regress after discontinuation of adalimumab. She began ustekinumab 45 mg every 12 weeks, which led to complete regression of her psoriasis. Due to persistent bowel symptoms, ustekinumab was increased to 135 mg every 8 weeks, with improvement. In this case, GP may have been related to recent streptococcal infection, or a complication of TNF-inhibitor therapy. Here, we show ustekinumab has potential as a therapeutic option for both GP and Crohn's disease.

Sign in / Sign up

Export Citation Format

Share Document